Skip to content
lifestyle.tophustler.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Marvel Biosciences Corp.
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
October 8, 2026
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
October 6, 2026
Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
August 5, 2026
New Autism Research to be Presented at European Purine Scientific Meeting
June 26, 2026
Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204
June 8, 2026
Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
May 20, 2026
Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
April 16, 2026
Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
March 30, 2026